THE FINAL STATS FOR #GU25 are IN‼️
Thank you very much @ASCO for a fantastic meeting!!
90 Million impressions Worldwide🌐
Thank you Colleagues for your Support!!
0
0
0
0
#GU25
Latest posts tagged with #GU25 on Bluesky
Trending
Posts tagged #GU25
A Great Day TWO of #GU25
Thank you very much ASCO for a fantastic meeting!!
55 Million impressions Worldwide🌐
Thank you Colleagues for your Support!!
1
0
0
0
How and when should HRR testing be integrated into prognostic and treatment strategies for mCRPC? This #MensHealthWeek, stay informed on the latest news and research in #prostatecancer with expert highlights from #ASCO25, #EAU25, and #GU25 #MedSky #MedEd
ow.ly/zrzg50W6jym
1
1
0
0
Catch-up with the latest data on #NMIBC management from this year’s congresses with our on-demand highlights. From emerging therapies at #GU25 to the use of AI for prognosis at #EAU25, stay informed on recent advances this #BladderCancerAwarenessDay #MedSky #MedicalEducation
ow.ly/aYPe50VOCSl
1
1
0
0
Here's @prof-nick-james.bsky.social at #GU25 discussing new data from the STAMPEDE trial showing that transdermal oestradiol patches can safely be used alongside androgen receptor pathway inhibitors for #ProstateCancer treatment.
#ProstateCancerAwarenessMonth
2
0
0
0
Residential-Specific Factors and ADT Use Influence HRQOL Outcomes in Bladder and Prostate Cancer #pcsm #GU25 @ascocancer.bsky.social www.onclive.com/view/residen...
1
0
0
0
First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC @ascocancer.bsky.social #GU25 #oncology
www.onclive.com/view/first-l...
3
0
0
0
Great to join the conversation at the @anzuptrials.bsky.social & #TheLimbic @ascocancer.bsky.social #GU25 ‘Highlights through an Australian lens' series in Melbourne chaired by #AndrewWeickhardt with a great panel featuring #DavidPook #ShahneenSandhu #BenTran & #ShomikSengupta @profiand.bsky.social
1
0
0
0
Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma @ascocancer.bsky.social #GU25 #oncology
www.onclive.com/view/cemipli...
1
0
0
0
Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC
@vumc-insights.bsky.social @ascocancer.bsky.social #kcsm #GU25
www.onclive.com/view/tivozan...
2
1
0
0
Dr Neeraj Agarwal of @huntsmancancer.bsky.social and #WhereisHoskin @officialuom.bsky.social @mcrcnews.bsky.social recap key studies from #GU25 + highlight research on prostate, bladder, and kidney cancer on the latest episode of the #ASCODailyNews Podcast: brnw.ch/21wR4ZB
4
1
0
0
Addition of CBM588 to Cabozantinib/Nivolumab Shows Potential in Metastatic RCC @cityofhope.bsky.social @ascocancer.bsky.social #GU25 #kcsm www.onclive.com/view/additio...
1
0
0
0
🎙️ @neerajagarwal.bsky.social of @huntsmancancer.bsky.social and Dr. Peter Hoskin of @official-uom.bsky.social recap key studies from #GU25 + highlight research on prostate, bladder, and kidney cancer on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/practice-...
8
2
1
1
What is the IMPACT of the data out of #GU25 in the treatment of Advanced #ProstateCancer ?
WATCH ON DEMAND TO FIND OUT 👉 buff.ly/3QIwe2p
Our collaborators at
@mirrorsmed would like to invite you to these case based discussions on ARASENS and ARANOTE with @BertrandTOMBAL and @PGrivasMDPhD
2
1
0
0
Efficacy and Safety of Nadofaragene Firadenovec Hold Up in NMIBC Real-World Study #blcsm #GU25 @ascocancer.bsky.social @mayocliniccancer.bsky.social www.onclive.com/view/efficac...
1
0
0
0
What is the IMPACT of the data out of #GU25 in the treatment of Advanced #ProstateCancer ?
WATCH ON DEMAND TO FIND OUT 👉 https://buff.ly/41Cr9iM
Our collaborators at Mirrors of Medicine would like to invite you to these case based discussions on ARASENS and ARANOTE
0
0
0
0
Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC @ascocancer.bsky.social #GU25 #oncology
www.onclive.com/view/durvalu...
2
0
0
0
We had the opportunity to attend ASCO #GU25. Read our summary and please share other highlights with us. ikcc.org/summary-of-k... #KidneyCancer
2
0
0
0
An insightful Abstract2Practice video by Our OncoAlert🚨 Colleague Dr. Petros Grivas🇺🇸 , where he breaks down the ARANOTE #ProstateCancer results👉 https://buff.ly/3D6NjQI
Find out how these results presented at ASCO #GU25 are applied in clinical practice.
1
0
0
0
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community oncologists. #GU25 | @clevelandclinic.bsky.social
www.targetedonc.com/view/aveluma...
0
0
0
0
Missed out on #GU25?
Listen to our latest podcast, and to a preview below, where
@prof-nick-james.bsky.social discusses updates from the STAMPEDE trial, and the benefits of transdermal estradiol patches in #prostatecancer!
#kcsm #uroonc #blcsm #pcsm @icr.ac.uk @ascocancer.bsky.social
3
2
1
0
ICYMI: Dr. Matthew Galsky, Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses the impact of the CheckMate-901 trial results on the frontline management of mUC for #ASCODailyNews: dailynews.ascopubs.org/do/championi...
#gucsm #GUonc #GU25
6
0
0
0
Thank you to all who tuned into our three poster presentations at ASCO #GU25!
We were thrilled to be able to highlight the ongoing clinical developments of the LEGEND study for patients with non-muscle invasive bladder cancer (#NMIBC).
Check out highlights below!
1
0
0
0
www.cancertherapyadvisor.com/reports/bene... #GU25 @ascocancer.bsky.social @prostatecancer.bsky.social
1
0
0
0
An insightful Abstract2Practice video by Our OncoAlert🚨 Colleague Dr. Petros Grivas🇺🇸 , where he breaks down the ARANOTE #ProstateCancer results👉 https://buff.ly/41146MS
Find out how these results presented at ASCO #GU25 are applied in clinical practice.
4
2
0
0
Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium @mdanderson.bsky.social @uofglasgow.bsky.social @cityofhope.bsky.social @danafarber.bsky.social @ascocancer.bsky.social #GU25 #pcsm #blcsm #kcsm
www.onclive.com/view/experts...
1
0
0
0
www.cancertherapyadvisor.com/reports/diet... #GU25 @ascocancer.bsky.social @prostatecancer.bsky.social @dgsomucla.bsky.social
1
0
0
0
Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC @ascocancer.bsky.social #GU25 #blcsm www.onclive.com/view/nadofar...
1
0
0
0
